Jazz Pharmaceuticals, Inc. insider trading
JAZZfinancial statementsForm 4 filings on EDGAR244 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at Jazz Pharmaceuticals, Inc. bought $0 of stock in the open market, and 4 sold $23M. Officers and directors accounted for $0 of purchases and $23M of sales. The last reported transaction was an open-market sale by Gala Renee D on October 6, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 7, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $23MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
244 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Gala Renee D | President & CEO, Director | open-market sale10b5-1 | 2,000 | $236.40 | $473K | 141,394 | Oct 7, 2026 |
| Oct 1, 2026 | Cozadd Bruce C | Director | open-market sale10b5-1 | 6,000 | $230.33 | $1M | 345,875 | Oct 5, 2026 |
| Sep 10, 2026 | Patil Neena M | EVP & Chief Legal Officer | open-market sale10b5-1 | 1,200 | $240.94 | $289K | 47,671 | Sep 14, 2026 |
| Sep 8, 2026 | Gala Renee D | President & CEO | tax withholding | 1,967 | $246.81 | $485K | 145,394 | Sep 10, 2026 |
| Sep 8, 2026 | Gala Renee D | President & CEO | open-market sale10b5-1 | 2,000 | $243.03 | $486K | 143,394 | Sep 10, 2026 |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | tax withholding | 1,412 | $243.03 | $343K | 23,830 | Sep 10, 2026 |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | tax withholding | 15 | $241.20 | $4K | 23,815 | Sep 10, 2026 |
| Sep 1, 2026 | Cozadd Bruce C | Director | open-market sale10b5-1 | 6,000 | $250.13 | $2M | 351,875 | Sep 2, 2026 |
| Aug 31, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | tax withholding | 2,076 | $241.39 | $501K | 25,258 | Sep 2, 2026 |
| Aug 31, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | tax withholding | 16 | $244.64 | $4K | 25,242 | Sep 2, 2026 |
| Aug 31, 2026 | Smith Mark Douglas | Director | tax withholding | 14 | $244.64 | $3K | 11,271 | Sep 2, 2026 |
| Aug 31, 2026 | Smith Mark Douglas | Director | tax withholding | 1,692 | $241.39 | $408K | 9,579 | Sep 2, 2026 |
| Aug 31, 2026 | Riedel Norbert G | Director | tax withholding | 14 | $244.64 | $3K | 8,615 | Sep 2, 2026 |
| Aug 31, 2026 | Riedel Norbert G | Director | tax withholding | 1,692 | $241.39 | $408K | 6,923 | Sep 2, 2026 |
| Aug 31, 2026 | Love Ted W | Director | tax withholding | 6 | $244.06 | $1K | 3,126 | Sep 2, 2026 |
| Aug 31, 2026 | Love Ted W | Director | tax withholding | 737 | $241.39 | $178K | 2,389 | Sep 2, 2026 |
| Aug 31, 2026 | Hamill Laura | Director | tax withholding | 14 | $244.06 | $3K | 8,524 | Sep 2, 2026 |
| Aug 31, 2026 | Hamill Laura | Director | tax withholding | 1,692 | $241.39 | $408K | 6,832 | Sep 2, 2026 |
| Aug 31, 2026 | Cook Jennifer E. | Director | tax withholding | 14 | $244.06 | $3K | 12,428 | Sep 2, 2026 |
| Aug 31, 2026 | Cook Jennifer E. | Director | tax withholding | 1,692 | $241.39 | $408K | 10,736 | Sep 2, 2026 |
| Aug 31, 2026 | Enright Patrick G | Director | tax withholding | 14 | $244.64 | $3K | 22,970 | Sep 2, 2026 |
| Aug 31, 2026 | Enright Patrick G | Director | tax withholding | 1,692 | $241.39 | $408K | 21,278 | Sep 2, 2026 |
| Aug 31, 2026 | McSharry Heather Ann | Director | tax withholding | 15 | $244.64 | $4K | 20,039 | Sep 2, 2026 |
| Aug 31, 2026 | McSharry Heather Ann | Director | tax withholding | 1,840 | $241.39 | $444K | 18,199 | Sep 2, 2026 |
| Aug 31, 2026 | Kennedy Patrick | Director | tax withholding | 15 | $244.06 | $4K | 8,292 | Sep 2, 2026 |
| Aug 31, 2026 | Kennedy Patrick | Director | tax withholding | 1,840 | $241.39 | $444K | 6,452 | Sep 2, 2026 |
| Aug 31, 2026 | Winningham Rick E | Director | tax withholding | 1,692 | $241.39 | $408K | 9,480 | Sep 2, 2026 |
| Aug 31, 2026 | Winningham Rick E | Director | tax withholding | 14 | $244.64 | $3K | 9,466 | Sep 2, 2026 |
| Aug 31, 2026 | Cozadd Bruce C | Director | tax withholding | 10 | $244.06 | $2K | 359,084 | Sep 2, 2026 |
| Aug 31, 2026 | Cozadd Bruce C | Director | tax withholding | 1,209 | $241.39 | $292K | 357,875 | Sep 2, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | option exercise | 26,116 | $113.10 | $3M | 111,223 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | option exercise | 884 | $113.10 | $100K | 112,107 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | option exercise | 27,584 | $137.12 | $4M | 139,691 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | option exercise | 2,916 | $137.12 | $400K | 142,607 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 18,187 | $247.86 | $5M | 124,420 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 11,423 | $248.67 | $3M | 112,997 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 18,113 | $250.02 | $5M | 94,884 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 19,639 | $250.60 | $5M | 75,245 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 9,259 | $251.95 | $2M | 65,986 | Aug 31, 2026 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | open-market sale10b5-1 | 300 | $252.76 | $76K | 65,686 | Aug 31, 2026 |
| Aug 5, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | tax withholding | 780 | $261.62 | $204K | 47,131 | Aug 7, 2026 |
| Aug 5, 2026 | Winningham Rick E | Director | award | 1,605 | $0.00 | — | 11,172 | Aug 7, 2026 |
| Aug 5, 2026 | Love Ted W | Director | award | 1,605 | $0.00 | — | 3,132 | Aug 7, 2026 |
| Aug 5, 2026 | Hamill Laura | Director | award | 1,605 | $0.00 | — | 8,538 | Aug 7, 2026 |
| Aug 5, 2026 | Kennedy Patrick | Director | award | 1,605 | $0.00 | — | 8,307 | Aug 7, 2026 |
| Aug 5, 2026 | Smith Mark Douglas | Director | award | 1,605 | $0.00 | — | 11,285 | Aug 7, 2026 |
| Aug 5, 2026 | Cook Jennifer E. | Director | award | 1,605 | $0.00 | — | 12,442 | Aug 7, 2026 |
| Aug 5, 2026 | Mulligan Seamus | Director | award | 1,605 | $0.00 | — | 1M | Aug 7, 2026 |
| Aug 5, 2026 | McSharry Heather Ann | Director | award | 1,605 | $0.00 | — | 20,054 | Aug 7, 2026 |
| Aug 5, 2026 | Enright Patrick G | Director | award | 1,605 | $0.00 | — | 22,984 | Aug 7, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Cozadd Bruce C | Chairman & CEO, Director | Oct 1, 2026 | open-market sale | 345,875 | — | $28M (20) | 12 of 20 |
| Iannone Robert | EVP, Global Head of R&D & CMO | Aug 27, 2026 | option exercise | 111,223 | — | $20M (7) | 7 of 7 |
| Patil Neena M | EVP & Chief Legal Officer | Sep 10, 2026 | open-market sale | 47,671 | — | $12M (14) | 3 of 14 |
| Carr Patricia | SVP, Chief Accounting Officer | Mar 9, 2026 | open-market sale | 6,512 | — | $2M (7) | 0 of 7 |
| Winningham Rick E | Director | Aug 31, 2026 | tax withholding | 9,480 | — | $2M (2) | 0 of 2 |
| Pearce Samantha | EVP, Chief Commercial Officer | Aug 5, 2026 | tax withholding | 47,131 | — | $2M (1) | 0 of 1 |
| Henderson Mary Elizabeth | SVP, Technical Operations | Sep 8, 2026 | tax withholding | 23,830 | — | $1M (2) | 0 of 2 |
| McSharry Heather Ann | Director | Aug 31, 2026 | tax withholding | 20,039 | — | $1M (2) | 0 of 2 |
| Gala Renee D | President & CEO, Director | Oct 6, 2026 | open-market sale | 141,394 | — | $959K (2) | 2 of 2 |
| Riedel Norbert G | Director | Aug 31, 2026 | tax withholding | 8,615 | — | $656K (1) | 0 of 1 |
| Smith Mark Douglas | Director | Aug 31, 2026 | tax withholding | 11,271 | — | $267K (1) | 1 of 1 |
| Mulligan Seamus | Director | Aug 5, 2026 | award | 1M | — | — | — |
| Enright Patrick G | Director | Aug 31, 2026 | tax withholding | 22,970 | — | — | — |
| Johnson Philip L | EVP & Chief Financial Officer | Jun 30, 2026 | tax withholding | 56,431 | — | — | — |
| Hamill Laura | Director | Aug 31, 2026 | tax withholding | 8,524 | — | — | — |
| Cook Jennifer E. | Director | Aug 31, 2026 | tax withholding | 12,428 | — | — | — |
| Kennedy Patrick | Director | Aug 31, 2026 | tax withholding | 8,292 | — | — | — |
| Love Ted W | Director | Aug 31, 2026 | tax withholding | 3,126 | — | — | — |
| O'Keefe Kenneth W | Director | Dec 2, 2025 | tax withholding | 25,811 | — | — | — |
| ORiordan Anne | Director | Aug 8, 2025 | tax withholding | 16,500 | — | — | — |
Questions
Are Jazz Pharmaceuticals, Inc. insiders buying or selling?
Over the twelve months to November 3, 2026, 11 insiders at Jazz Pharmaceuticals, Inc. sold $70M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $70M. Only open-market purchases and sales are counted.
Who sold the most Jazz Pharmaceuticals, Inc. stock in the last year?
Cozadd Bruce C (Director) sold $28M in 20 open-market sales over the twelve months to November 3, 2026.
Do Jazz Pharmaceuticals, Inc. executives sell under 10b5-1 plans?
25 of the 59 open-market sales in the last twelve months (42%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Jazz Pharmaceuticals, Inc.
- Jazz Pharmaceuticals, Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.